AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03951831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
Study NCT03276026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
Study NCT03276026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
Study NCT04238481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pudexacianinium chloride
Description: Intravenous
Study NCT00979966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: 25 mg intravenously, once weekly infusion
Study NCT00979966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
Study NCT03303170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sebacia Microparticles
Description: Topical microparticle suspension
Study NCT03303170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:Yag Laser
Description: Laser delivering 1064 nm wavelength light
Study NCT03750760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alirocumab
Description: PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
Study NCT03750760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
Study NCT03750760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Cholesterol absorption inhibitor
Study NCT01517165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT01517165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01498393 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser treatment
Description: Laser treatment to Improve the Appearance of Onychomycosis
Study NCT01263678 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Coaching
Description: Decision support coaching will be provided after the participant has viewed the decision aid
Study NCT01263678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patient views DA and completes post DA survey.
Study NCT00835198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone; Tretinoin
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Study NCT00835198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
Study NCT00350870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: disulfiram
Description: 250mg per day of Disulfiram plus CBT
Study NCT00350870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus CBT
Study NCT02697032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg
Study NCT02697032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDHT PET
Description: PET scan
Study NCT01748032 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive training
Description: 20 minutes/day for 5 sequential working days
Study NCT02741024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine-Artesunate (ASAQ)
Description: Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
Study NCT02741024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine (AL)
Description: Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
Study NCT00851500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-604
Description: K-604 is given for 26 weeks
Study NCT02989584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Study NCT02989584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02989584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03146962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
Study NCT00851500 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets are given for 26 weeks
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A: Peg-interferon alpha-2a & Ribavirin
Description: Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA \< 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: Peg-interferon alpha-2a & Ribavirin
Description: Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: Peg-interferon alpha-2a & Ribavirin
Description: Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D: Peg-interferon alpha-2a & Ribavirin
Description: Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Peg-interferon alpha-2a & Ribavirin
Description: Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
Study NCT01937728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F: Peg-interferon alpha-2a & Ribavirin
Description: Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.
Study NCT01315678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
Description: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Study NCT01315678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
Description: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment
Study NCT01516697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental
Description: Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
Study NCT01516697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
Study NCT00719134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxalt
Description: anti-migraine drug
Study NCT00719134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pills
Study NCT00719134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pills
Description: placebo pills
Study NCT00719134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pills
Description: placebo pills
Study NCT01720121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed, digital video disc
Description: The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
Study NCT01302600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1ml/kg once a day with food at dinner.
Study NCT06792669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation training to evaluate the participants' manual skill improvement
Study NCT04608487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous infusion
Study NCT04608487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous infusion
Study NCT04608487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Intravenous infusion
Study NCT00350870 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Contingency Management
Description: Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
Study NCT00350870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram plus Contingency Management
Description: 250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
Study NCT03186508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimize Sleep (OS)
Description: All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.
Study NCT03186508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimize Sleep-Plus (OS-Plus)
Description: All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact.
Study NCT00822419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: lidocaine cream 5%
Study NCT00822419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine 5%
Study NCT00822419 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: non-drug cream
Description: will be put on the skin
Study NCT00570011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
Study NCT00570011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
Study NCT04003207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Growth hormone
Description: Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
Study NCT02285023 — intervention group
Intervention type: OTHER
Intervention: CU-Q2oL
Description: The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire.
Study NCT03268954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine intravenous or subcutaneous formulation.
Study NCT03268954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study NCT04113733 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
Study NCT03669757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 134310
Description: Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
Study NCT03669757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 134310 vehicle
Description: Active substance: none
Study NCT03669757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone valerate ointment (class III steroid)
Description: Active substance: betamethasone valerate
Study NCT03913013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Focused Treatment with MCC App
Description: 12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
Study NCT03913013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment with MCC App
Description: 12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
Study NCT01108731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study.
Study NCT01108731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study.
Study NCT01924273 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Talaporfin sodium
Description: Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
Study NCT02082080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT02082080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social support
Study NCT03608501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study NCT00157196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide \[L-BLP25\]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
Study NCT00157196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
Study NCT00157196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best standard of care (BSC)
Description: The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
Study NCT03848130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Knee Taping with Home Exercises
Description: Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings \& ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
Study NCT03848130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lateral wedge insoles with Home Exercises
Description: Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
Study NCT03848130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy with Home Exercises
Description: Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors \& abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
Study NCT03944265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participate in treatment decision counseling session
Study NCT03608501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide capsules.
Study NCT03944265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03944265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT03608501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study NCT02655939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reflex Plus
Description: Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
Study NCT02655939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose,Orange flavor and sucralose
Study NCT01446900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
Study NCT01446900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: 0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
Study NCT01672697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) and Behavioral Therapy (BT)
Description: 1. Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~2. Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment.